News

Joel Schlessinger, MD, shares his atopic dermatitis insights.

Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.

ICYMI, this week we had articles about JNJ-2113 advancing in plaque psoriasis. and ulcerative colitis clinical development, finding balance during busy conference seasons, numerous late-breaking announcements from EADV, and more.

Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.

The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.

UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

Last week was Body-Focused Repetitive Behaviors Awareness Week. Related to dermatology, dermatillomania, also known as skin picking disorder, is a condition that requires empathy and understanding year round.

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

This month's cover feature delves into the new applications and use of AI in dermatology and considers how AI can support clinicians rather than hinder them.

November is Hyperhidrosis Awareness Month, and dermatology clinicians are gearing up for another month of raising awareness to improve patient outcomes.

The PC Project provides patients with access to the International PC Research Registry for clinical help with their rare and painful skin condition.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

AbbVie announced the 24- and 52-week data at EADV 2023.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

The impact of acne conglobata on individuals underscores the crucial role dermatologists play in providing effective diagnosis, treatment, and emotional support.

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.

Sexual and gender minority patients with chronic inflammatory skin diseases may be disproportionately influenced by cost and noncost obstacles to health care.

Dermatologist Diego Ruiz Dasilva, MD, FAAD, and a patient with atopic dermatitis discuss the patient journey from initial symptoms to diagnosis to treatment selection.

Kyverna Therapeutics can now initiate its phase 1/2 open-label, multicenter study of KYV-101.

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

Experts discuss the treatment landscape of generalized pustular psoriasis as well as review difficult cases of GPP.

The impact begins in utero, with the diet and health of the mother playing a key role in the potential for a child to develop diseases.

This week’s collection of the latest dermatologic studies covers the incidence of keratinocyte carcinomas, upadacitinib used to treat discoid lupus erythematosus, considerations about hair camouflage for Black women with alopecia, and parent perspectives of infants undergoing surgical treatment for congenital melanocytic nevus.

Kristina Collins, MD, delves into the importance of being present in the moments you have control over and making self-care a priority on the road.

This World Mental Health Day, Zoe Diana Draelos, MD, discusses the importance of prioritizing physician well-being in order to prevent burnout, or as Draelos instead refers to it, "stasis."